张英英,陈 华

宫颈癌是我国女性最常见的妇科恶性肿瘤，最近几年发现，宫颈癌的发病逐渐表现出年轻化的趋势，针对这种年轻化的趋势，越来越多的宫颈癌患者不仅注重治疗后的生存率大多数患者开始更加注重治疗后的生活质量，对于宫颈癌患者的治疗早期通常以手术治疗为主，中晚期大多采用放射治疗，放射治疗会对患者卵巢功能造成不同程度的损伤，导致患者会出现潮热、出汗、烦躁、失眠、泌尿生殖系统萎缩和四肢酸痛等围绝经期症状，这些围绝经期症状严重影响宫颈癌放疗后患者的生活质量。现如今，越来越多的人重视患者治疗后的生活质量问题，因此大量研究表明，激素替代治疗(Hormone replacement therapy，HＲT)对于改善各种原因所致的围绝经期症状存在一定的效果，相比之下是目前最有效且最方便的办法．但是国内外对于HRT在宫颈癌放疗后患者中应用的安全性仍存在一定争议，HRT在宫颈癌放疗后患者中的应用仍有待进一步探索。

宫颈癌；放射治疗；卵巢功能；激素替代治疗

[1] Sherman ME,Wang SS,Carreon J,et al.Mortality trends for cervical squamous and adenocarcinoma inthe United States.Relation toincidence and survival[J].Cancer,2005,103(6):1258-1264. [2] 中华医学会妇产科学分会绝经学组.绝经期管理与激素补充治疗临床应用指南(2012版)[J].中华妇产科杂志,2013,48(10):795-799. [3] Panay N,Hamoda H,AryaR,et al.The 2013 British Menopause Society&Women's Health Concern recommendations onhormone replacement therapy[J].Menopause Int,2013,19(2):59-68. [4] Sherman ME,Wang SS,Carreon J,et al.Mortality trends for cervical squamous and adenocarcinoma inthe United States.Relation toincidence and survival[J].Cancer,2005,103(6):1258-1264. [5] Stroud JS,Mutch D,Rader J,et al.Effects of cancer treatment on ovarian function[J].Fertility and Sterility,2009,92(2):417-427. [6] 乔峤,宋静慧;年轻宫颈癌患者移位卵巢血流阻力指数与内分泌功能的关系[J].华中科技大学学报:医学版,2010,39(1):33-36. [7] Bloemers M C W M,Portelance L,Legier C,et al.Preservation of ovarian function by ovarian transposition prior to concurrent chemotherapy and pelvic radiation for cervical cancer.A case report and review of the literature[J].European Journal of Gynaecological Oncology,2010,31(2):194-197. [8] 卫生部继续医学教育委员会.女性生殖内分泌性激素补充疗法A.见:林守清主编.女性生殖内分泌性激素补充疗法[M].北京:中国协和医科大学出版社,1999,80-88. [9] Hays J,Ockene JK,Brunner RL,et al.Effects of estrogen plusprogestin on health-related quality of life[J].N Engl J Med,2003,348(19):1839-1854. [10] Cauley JA,Robbins J,Chen Z,et al.Effects of estrogen plusprogestin on risk of fracture and bone mineral density:the Women′s Health Initiative randomized trial[J].JAMA,2003,290(13):1729-1738. [11] 郁琦,中华医学会妇产科学分会绝经学组.绝经过渡期和绝经后期激素补充治疗临床应用指南(2009版)[J].中华妇产科杂志, 2010,45(8):635-638. [12] Daayana S,Holland CM.Hormone replacement therapy and the endometrium[J],Menopause Int,2009,15(3):134-138. [13] Boardman HM,Hartley L,Eisinga A,et al.Hormone therapy for preventing cardiovascular disease in post-menopausal women[J]. Cochrane Database Syst Rev,2015,3:CD002229. [14] Walsh BW,Spiegelman D,Morrissey M,et al.Relationship between serum estradiol levels and the increases in high-density lipoprotein levels in postmenopausal women treated with oral estradiol[J].J Clin Endocrinol Metab,1999,84(3):985-989. [15] Ploch E.Hormonal replacement therapy in patients after cervical cancer treatment[J].Gynecol Oncol,1987,26(2):169-177. [16] 王金桃,高尔生,程玉英,闫建文,丁玲;内源性雌､孕激素与人乳头瘤病毒在宫颈癌发生中的协同作用研究[J],中华流行病学杂志, 2005年5月第26卷第5期Chin J EpidemiolMay 2005 Vol.26 No.5. [17] Castellsague X,BoschFX,MunozN.Environmental co-factors inHPV carcinogenesis.Virus Res,2002,89:191-199. [18] Ramachandran Balaji.Functional association of oestrogen receptors with HPV infection in cervical carcinogenesis.[J].Endocrine-related cancer, 2017,24(4):99-108. [19] 刘萌,雌激素对宫颈癌细胞生物学行为的影响及在宫颈病变发生中的作用[J],山东大学硕士学位论文,2020;0-67. [20] Lacey JV Jr,Brinton LA,Bares WA,et al.Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix[J].Gynecol Oncol,2000,77(1):149-154. [21] 于汀,孙涛,张艺,等.PTEN､HPV16/18-E6蛋白和雌激素受体在宫颈腺癌中的表达及其临床意义[J].生物技术通讯,2009,20(3):360-362. [22] 贾美群,陈曾燕,李海波,雌激素和孕激素对人宫颈癌细胞体外生长影响的研究[J],中华肿瘤防治杂志,2009,16(6):431-433｡ [23] 刘若梅.性激素替代疗法在年轻宫颈鳞癌术后患者中的应用[J].实用肿瘤学杂志,2008,22(3):240. [24] 安云婷､喻金梅､乔志强､邹美燕､李霞,年轻宫颈癌患者放疗后激素替代治疗的临床观察[J],实用癌症杂志,2020年12月第35卷第12期. [25] 于月成.宫颈癌综合治疗后激素替代冶疗85例[J].第四军医大学学报,2005,25(8):743-744. [26] 陈蓉,《中国绝经管理与绝经激素治疗指南2023版》解读[J].协和医学杂志,2023,14(3):514-519. [27] LIU P,ZHANG C,LIAO Y,et al.High expression of PTPRM predicts poor prognosis and promotes tumor growth and lymph node metastasis in cervical cancer[J].Cell Death Dis,2020,11(8):687.

点击下载PDF